Company Overview - The Oncology Institute (NASDAQ: TOI) focuses on uniting cancer care practices across the United States to enhance the efficiency of oncological treatments and patient management [1] - The primary objective is to reduce costs associated with cancer care [1] Services Offered - The company provides a range of patient services aimed at improving the overall management of cancer patients [1] Industry Context - The healthcare sector is complex, and financial professionals require scientific and clinical expertise to navigate it effectively [1] - There is a growing need for strategies that bridge the gap between advanced scientific research and financial decision-making in life sciences [1]

Financial Data and Key Metrics Changes - The total revenue for Q2 2025 was 6,000 million baht, representing a decline of 3.6% year-over-year [26][27] - EBITDA margin reached a record high of 41.6%, while net profit margin was 30.4%, slightly up from 30.5% in the previous year [9][33] - EPS was reported at 40 baht, with a dividend payout ratio of 44% for the interim dividend, up from 41% the previous year [13] Business Line Data and Key Metrics Changes - Revenue from non-Thai patients decreased by 6.6%, while Thai patient revenue slightly declined by 0.2% [26][28] - The outpatient service revenue contribution increased to 51% from 49% in the first half of the previous year, while inpatient service revenue remained at 50% [31] - The MDA segment saw a significant decline of 12.4%, primarily from Qatar, Kuwait, and Oman, while the Indo-China segment increased by 0.4% [29][30] Market Data and Key Metrics Changes - Middle Eastern business showed strong growth, with Qatar up 18%, UAE up 46%, Oman up 28%, and Saudi Arabia up 54% [5][6] - The company experienced a decline in revenue from Chinese patients, with a drop of over 30% to 40% year-over-year due to safety concerns [65] - The Cambodian market is expected to stabilize, which could improve OPD footfalls and admissions in the future [66] Company Strategy and Development Direction - The company is focusing on expanding its cancer care services, recognizing the growing global cancer crisis and the need for comprehensive care [89][90] - Plans for a new cancer care facility are underway, aimed at enhancing patient experience and integrating advanced technologies [95] - The company is actively negotiating with the Kuwaiti government regarding patient payments and potential future collaborations [39][46] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for Q3 2025, expecting stronger performance compared to the first half of the year [16][25] - The company is cautiously optimistic about the return of Kuwaiti patients, emphasizing the importance of quality care and governance [46][60] - The geopolitical situation in Cambodia and China is impacting patient flow, but management is hopeful for recovery in these markets [66][70] Other Important Information - The company received recognition from Newsweek as one of the best specialized hospitals in Thailand, ranking number one in six out of nine specialties [79] - A successful disease screening campaign generated nearly 96 million baht in revenue within two months [82] - The company upgraded its robotic surgery capabilities, expanding to more specialties and training additional surgeons [84] Q&A Session Summary Question: What is the outlook for the Kuwaiti market? - Management indicated that discussions with Kuwaiti officials are ongoing, and there is cautious optimism about future patient flow and payments [39][46] Question: How is the company addressing the decline in Chinese patients? - The company is expanding its presence in China and engaging in online outreach to improve connections with potential patients [67][68] Question: What are the expectations for the second half of 2025? - Management expects stronger performance in the second half compared to the first half, driven by recovery in key markets [16][25]

Core Insights - The Oncology Institute, Inc. (TOI) is one of the largest value-based oncology groups in the United States, focusing on specialized cancer care [1][2] - TOI will participate in B. Riley's 25th Annual Institutional Investor Conference on May 21, 2025, with key executives attending [1] Company Overview - Founded in 2007, TOI provides value-based cancer care to over 1.8 million patients, including services like clinical trials and transfusions [2] - The organization employs over 120 clinicians and has more than 700 staff across 70 clinic locations, aiming to improve oncology care [2]